AGY — Allergy Therapeutics Share News
0.000.00%
Last trade - 00:00- £300.80m
- £317.46m
- £55.04m
Brief: Allergy Therapeutics Targeting HKEX Listing Effective First Half Of 2026
Brief: Allergy Therapeutics Screening For Grass MATA MPL to Complete By Early Q1 2026
Allergy Therapeutics - Warrant Exercise and Paydown of Debt
RCS - Allergy Therapeutics - Grass MATA MPL Publications in Allergy Journal
Allergy Therapeutics - Trading update for the year ended 30 June 2025
Allergy Therapeutics - PDMR Dealings
RCS - Allergy Therapeutics - Allergy Therapeutics presents findings at EAACI
RCS - Allergy Therapeutics - EAACI Early Career Research Award
Brief: Allergy Therapeutics Posts H1 Net Income GBP -11.085 Million
Allergy Therapeutics - Interim Results for six months ended 31 Dec 2024
Brief: Allergy Therapeutics Enters Final Phase Of Treatment In Phase I/IIA VLP Peanut Protect Trial
Allergy Therapeutics - New Executive Long Term Incentive Awards
RCS - Allergy Therapeutics - Presentations at 2025 AAAAI / WAO Joint Congress
Brief: Allergy Therapeutics Announces Grass Mata Mpl Phase III Data Published In Allergy
Allergy Therapeutics - Grant of Options
Brief: Allergy Therapeutics Posts H1 Rev 34 Mln Stg
Allergy Therapeutics - Half Year Trading update
Allergy Therapeutics - PDMR Dealing and Total Voting Rights
Allergy Therapeutics - Director/PDMR Shareholding